Market Research Logo

Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Non-Small Cell Lung Cancer - Pipeline Review, H1 2015’, provides an overview of the Non-Small Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Non-Small Cell Lung Cancer Overview
Therapeutics Development
Non-Small Cell Lung Cancer – Therapeutics under Development by Companies
Non-Small Cell Lung Cancer – Therapeutics under Investigation by Universities/Institutes
Non-Small Cell Lung Cancer – Pipeline Products Glance
Non-Small Cell Lung Cancer – Products under Development by Companies
Non-Small Cell Lung Cancer – Products under Investigation by Universities/Institutes
Non-Small Cell Lung Cancer – Companies Involved in Therapeutics Development
Non-Small Cell Lung Cancer – Therapeutics Assessment
Drug Profiles
Non-Small Cell Lung Cancer – Recent Pipeline Updates
Non-Small Cell Lung Cancer – Dormant Projects
Non-Small Cell Lung Cancer – Discontinued Products
Non-Small Cell Lung Cancer – Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2015
Number of Products under Development for Non-Small Cell Lung Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Development by Companies, H1 2015 (Contd..12)
Number of Products under Development by Companies, H1 2015 (Contd..13)
Number of Products under Development by Companies, H1 2015 (Contd..14)
Number of Products under Development by Companies, H1 2015 (Contd..15)
Number of Products under Development by Companies, H1 2015 (Contd..16)
Number of Products under Development by Companies, H1 2015 (Contd..17)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Development by Companies, H1 2015 (Contd..18)
Products under Development by Companies, H1 2015 (Contd..19)
Products under Development by Companies, H1 2015 (Contd..20)
Products under Development by Companies, H1 2015 (Contd..21)
Products under Development by Companies, H1 2015 (Contd..22)
Products under Development by Companies, H1 2015 (Contd..23)
Products under Development by Companies, H1 2015 (Contd..24)
Products under Development by Companies, H1 2015 (Contd..25)
Products under Development by Companies, H1 2015 (Contd..26)
Products under Development by Companies, H1 2015 (Contd..27)
Products under Development by Companies, H1 2015 (Contd..28)
Products under Development by Companies, H1 2015 (Contd..29)
Products under Development by Companies, H1 2015 (Contd..30)
Products under Development by Companies, H1 2015 (Contd..31)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Non-Small Cell Lung Cancer – Pipeline by 4SC AG, H1 2015
Non-Small Cell Lung Cancer – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
Non-Small Cell Lung Cancer – Pipeline by AB Science, H1 2015
Non-Small Cell Lung Cancer – Pipeline by AbbVie Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by ACEA Biosciences, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Adaptimmune Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Advanced Cancer Therapeutics, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Advenchen Laboratories, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Allinky Biopharma, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Altor BioScience Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Ambryx Biotechnology, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Amgen Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by AndroScience Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Arch Biopartners, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Ariad Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Arog Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by ArQule, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Array BioPharma Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Ascenta Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Astellas Pharma Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by AstraZeneca Plc, H1 2015
Non-Small Cell Lung Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Axelar AB, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Azaya Therapeutics Incorporated, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Basilea Pharmaceutica AG, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Bayer AG, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Benitec Biopharma Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by BerGenBio AS, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Beta Pharma, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by BIND Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by BIOCAD, H1 2015
Non-Small Cell Lung Cancer – Pipeline by BioCancell Ltd, H1 2015
Non-Small Cell Lung Cancer – Pipeline by BioLineRx, Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Biothera, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Boston Biomedical, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Calithera Biosciences, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by CanBas Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cantex Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by CASI Pharmaceuticals Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by cCAM Biotherapeutics Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Celgene Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by CellAct Pharma GmbH, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Celldex Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cellectar Biosciences, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cellectis S.A., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cellmid Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Celltrion, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Centrose Llc, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Chipscreen Biosciences Ltd, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Clovis Oncology, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Conkwest, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Corcept Therapeutics Incorporated, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Critical Outcome Technologies Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by CTI BioPharma Corp., H1 2015
Non-Small Cell Lung Cancer – Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by CureVac GmbH, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by DanDrit Biotech A/S, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by DEKK-TEC, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by DiNonA Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Domainex Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by DormaTarg, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Eagle Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Eisai Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Eleison Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Eli Lilly and Company, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Endocyte, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by EnGeneIC Ltd, H1 2015
Non-Small Cell Lung Cancer – Pipeline by EntreChem, S.L., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Eudendron S.r.l., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Exelixis, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Five Prime Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Fortress Biotech, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Ganymed Pharmaceuticals AG, H1 2015
Non-Small Cell Lung Cancer – Pipeline by GeneFrontier Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Genelux Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Genentech, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Genmab A/S, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Genor BioPharma Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Genosco, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Gilead Sciences, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by GlaxoSmithKline Plc, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Globeimmune, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by GlycaNova Norway AS, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Glycotope GmbH, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Golden Biotechnology Corp., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Halozyme Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Heat Biologics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by HEC Pharm Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Helix BioPharma Corp., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Hospira, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Humanetics Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Hutchison MediPharma Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Ignyta, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Immune Design Corp., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Immune Pharmaceuticals Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by ImmunGene, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by ImmunoFrontier, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by ImmunoGen, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Immunome Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Immunomedics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Incanthera Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Incuron, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Incyte Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Intezyne, Inc, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Io Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Johnson & Johnson, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Juno Therapeutics Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Kadmon Corporation, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by KAEL-GemVax Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Loxo Oncology, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Mabion SA, H1 2015
Non-Small Cell Lung Cancer – Pipeline by MacroGenics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Mebiopharm Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by MedImmune, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Merck & Co., Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Merck KGaA, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Mersana Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Mirati Therapeutics Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Mirna Therapeutics, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by MolMed S.p.A., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Morphotek, Inc., H1 2015
Non-Small Cell Lung Cancer – Pipeline by NanoCarrier Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by Natco Pharma Limited, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Nektar Therapeutics, H1 2015
Non-Small Cell Lung Cancer – Pipeline by NeoPharm Co., Ltd., H1 2015
Non-Small Cell Lung Cancer – Pipeline by NewLink Genetics Corporation, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Nimbus Therapeutics, LLC, H1 2015
Non-Small Cell Lung Cancer – Pipeline by Novartis AG, H1 2015
Non-Small Cell Lung Cancer – Pipeline by NuCana BioMed Limited, H1 2015
List of Figures
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2015
Number of Products under Development for Non-Small Cell Lung Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report